And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...

Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL" ...

The FDA has issued a complete response letter for an oral selective glucocorticoid receptor antagonist under investigation ...

As for safety, the most common adverse reactions reported with treatment were mild to moderate nausea, edema, pain in extremities and back, and fatigue. No cases of relacorilant-induced hypokalemia, ...

Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application ...

Corcept Therapeutics (CORT) leverages Korlym’s commercial success in hypercortisolism, generating $559.3M in nine-month 2025 ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics stock falls after FDA rejects relacorilant for hypertension secondary to hypercortisolism; company to ...

To the mind of Sean Maduck, president of Corcept Endocrinology, the target audience of patients at the center of its recent direct-to-consumer (DTC) marketing push often go through 10-plus doctors ...

Please provide your email address to receive an email when new articles are posted on . The percentage of adults with hypercortisolism and difficult-to-control type 2 diabetes was higher than ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed. Among 136 patients, ...